|
|
 |
| Primary Symbols & Exchanges: |
| MYG - Toronto |
| - Pink Sheets |
|
|
| Primary Industry: |
| Biotechnology |
|
|
|
|
|
|
Thomson Financial Business Description:
| The Group's principal activities are to discover, develop and commercialize novel therapeutics for cancer and infectious diseases. The Group has two cancer product candidates MG98 and MGCD0103, in clinical trials in the United States, Canada and Europe. MG98 is partnered with MGI Pharma for North American rights and MGCD0103 is partnered with Taiho Pharmaceutical, a leading Japanese oncology company, for certain Asian rights. In addition, The Group has a portfolio of chemistry-driven research programs including HDAC inhibitors for other non-oncology large market indications and kinase inhibitors for cancer. It focuses on enzyme that are novel, play key roles in diseases, can potentially be exploited in multiple indications beyond oncology and infectious diseases. The Group operates in Canada, the United States, Japan, United Kingdom and Austria. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on MethylGene, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
